Radium-223 and atezolizumab in platinum refractory urothelial carcinoma with bone metastases: NCT03208712. Background: BCG unresponsive NMIBC includes patients with persistent high-grade disease or ...

The findings could play a key role in guiding treatment choices, ImmunityBio said. ・ImmunityBio will present new research on intravesical recombinant BCG in patients who have not previously received ...

N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. Superficial bladder ...

If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your ...

( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it will present new treatment comparison results evaluating ANKTIVA ® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Credit: Getty Images Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer.

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Novel immunotherapies and chemotherapies hold promise as non-surgical salvage options. Recent advances in our understanding of systemic immunotherapy, however, have transformed the management of ...

SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals presented the first results from an ongoing Phase 3 trial in Japan assessing the efficacy and safety of nadofaragene firadenovec in ...